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A B S T R A C T
Even though the receptor activator of the nuclear factor-κB ligand (RANKL) and its receptor RANK have an
exclusive role in osteoclastogenesis, the possibility of RANKL/RANK-independent osteoclastogenesis has been
the subject of a long-standing debate in bone biology. In contrast, it has been reported that calvarial injection of
TNF-ɑ elicits significant osteoclastogenesis in the absence of RANKL/RANK in NF-κB2- and RBP-J-deficient mice,
suggesting that inflammatory challenges and secondary gene manipulation are the prerequisites for RANKL/
RANK-deficient mice to develop osteoclasts in vivo. Here we report that, even in the absence of RANKL (Rankl−/
−), cherubism mice (Sh3bp2KI/KI) harboring the homozygous gain-of-function mutation in SH3-domain binding
protein 2 (SH3BP2) develop tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts
spontaneously. The Sh3bp2KI/KI Rankl−/− mice exhibit an increase in tooth exposure and a decrease in bone
volume/total volume compared to Sh3bp2+/+ Rankl−/− mice. The multinucleated cells were stained positively
for cathepsin K. Osteoclastic marker gene expression in bone and serum TRAP5b levels were elevated in
Sh3bp2KI/KI Rankl−/− mice. Elevation of the serum TNF-ɑ levels suggested that TNF-ɑ is a driver for the RANKL-
independent osteoclast formation in Sh3bp2KI/KI mice. Our results provide a novel mutant model that develops
osteoclasts independent of RANKL and establish that the gain-of-function of SH3BP2 promotes osteoclastogen-
esis not only in the presence of RANKL but also in the absence of RANKL.
1. Introduction
Osteoclasts are bone-degrading multinucleated cells critical for
homeostatic bone remodeling and pathologic osteolysis (Novack,
2016). Histologically, the multinucleated cells are positive for tartrate-
resistant acid phosphatase (TRAP) on the bone surfaces. Even though
previous studies have established that the receptor activator of nuclear
factor-κB ligand (RANKL) and its receptor RANK play a crucial role in
osteoclast formation, RANKL/RANK-independent osteoclastogenesis in
in vivo conditions of “wild-type mice” has been a long-standing debate
(Tanaka, 2017). Recently, a study suggested the ability of wild-type
osteoclast precursors to differentiate into functional osteoclasts in vivo
in the absence of RANK (O'Brien et al., 2016). However, it is very dif-
ficult to exclude the possibility of incomplete deletion of the Rank,
because inducible Mx1-Cre system was used to delete Rankl in the re-
port (Okamoto et al., 2017). Instead, in vivo RANK/RANKL-independent
osteoclastogenesis in a calvarial TNF-ɑ injection model has been de-
monstrated in mice with deletion of signaling mediators such as NF-κB2
and RBP-J (Yao et al., 2009; Zhao et al., 2012).
Cherubism (OMIM#118400) is an autosomal-dominant craniofacial
disorder in children characterized by expansive destruction of the
maxilla and mandible. Gain-of-function mutations in the signaling
adaptor SH3-domain binding protein 2 are responsible for the rare
disorder (Ueki et al., 2001). We have shown that homozygous P416R
knock-in (KI) mice (Sh3bp2KI/KI) harboring the most common mutation
in cherubism patients recapitulate the features of human cherubism by
developing spontaneous fibrous inflammatory lesions and by exhibiting
increased osteoclast formation in the jaw (Ueki et al., 2007). Hetero-
zygous and homozygous cherubism mutations promote osteoclasto-
genesis induced by receptor activator of nuclear factor-κB ligand
(RANKL) and tumor necrosis factor-alpha (TNF-ɑ) (Ueki et al., 2007;
Mukai et al., 2014).
Here, we show that homozygous Sh3bp2KI/KI mutant mice sponta-
neously develop TRAP-positive (+) multinucleated osteoclasts even
when RANKL is absent. The Sh3bp2KI/KI Rankl−/− osteoclasts are also
positive for cathepsin K. Reduced bone mass and increased levels of
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serum markers for osteoclasts in Sh3bp2KI/KI Rankl−/− mice compared
to Sh3bp2+/+ Rankl−/− mice suggest that Sh3bp2KI/KI Rankl−/− os-
teoclasts are functionally active for bone resorption. Our data show that
SH3BP2 has an in vivo regulatory role in promoting the differentiation
cascade of osteoclast progenitors to mature osteoclasts not only in the
presence of RANKL but also in the absence of RANKL. Also, the
Sh3bp2KI/KI Rankl−/−mice provide a new piece of evidence that genetic
manipulation is necessary for developing functional osteoclasts in the
absence of RANK/RANKL.
2. Materials and methods
2.1. Mice
All animal experiments in this study were performed according to
protocols approved by the IACUCs of the University of Missouri-Kansas
City and Indiana University. Sh3bp2KI/KI mice have been created pre-
viously (Ueki et al., 2007). RANKL-deficient (Rankl−/−) mice were
created by crossing Ranklfl/fl mice with EIIa-Cre mice. Ranklfl/fl
(#018978) and EIIa-Cre (#003724) mice were obtained from the
Jackson laboratory (Bar Harbor, ME, USA). All mice were crossed and
created on the mix background of C57BL/6 and 129 × 1/SvJ under
specific pathogen-free conditions and analyzed at 20 weeks old.
2.2. Ex-vivo microCT (μCT) analysis
Jaw bone and femur from 20-week old mice were fixed with 4%
paraformaldehyde (PFA) in PBS for 24 h and soaked in 70% ethanol for
scanning with the Skyscan 1174 (Bruker, Kontich, Belgium). Scanning
conditions are as follows: 80 kV X-ray energy, 6.67 μm pixel size, and
0.4° rotation step with 3000 ms of exposure time. Scanned data were
reconstructed with NRecon software (Bruker) with 0 to 0.16 of dynamic
range. 3D images were created using CTVox software (Bruker) based on
volume rendering method. Reconstructed data were aligned using
Dataviewer software (Bruker). The % of exposed tooth width was
measured using the midpoint of the lower 3rd molar. Femur length and
bone volume/tissue volume of trabecular bone (within one-fourth
length of the femur from the middle point toward the distal end) were
measured with the CTAnalyzer software (Bruker).
2.3. Histology
After μCT analysis, mandible and femur were decalcified with EDTA
(0.5 M, pH 7.2) and embedded in paraffin. Six μm sections were sub-
jected to hematoxylin and eosin (H&E) and TRAP staining, and im-
munohistochemistry for Cathepsin K. Images were captured using the
BZ-X800 microscope (Keyence, Osaka, Japan).
2.4. Histomorphometry of TRAP-positive osteoclasts
The number of TRAP+ cells underneath the growth plate of the
distal end of the femur was measured by Bioquant (Bioguant Image
Analysis Corporation, Nashville, TN). Trabecular bone within 3 mm
underneath the growth plate was separated into three regions (1 mm
each) and the number of TRAP+ cells was counted in each region of
interest (ROI). Two sections separated by at least 30 μm were analyzed
for each mouse and the numbers were averaged.
2.5. Immunohistochemical staining
Tissue sections were deparaffinized and rehydrated, then en-
dogenous peroxidase was blocked with 3% H2O2/PBS solution. After
blocking with 2% goat serum, sections were incubated with an antibody
against Cathepsin K (ab19027, Abcam) overnight at 4 °C. After washing
with PBS, sections were incubated with biotinylated goat secondary
antibody (Vector Laboratories, Burlingame, CA, USA) for 60 min at
room temperature followed by treatment with Vectastain elite ABC kit
(Vector Laboratories). Sections were colored using ImmPACT DAB
(Vector Laboratories) and counterstained with hematoxylin.
2.6. RNA extraction from femurs
After removing soft tissues, head and distal end of the femur were
cut off. The remaining part of the femur was flash frozen in liquid ni-
trogen and crushed in powder using a tissue pulverizer (Cellcrusher
Limited, Schull, Ireland) for RNA isolation (Ribozol, VWR, Radnor, PA,
USA).
2.7. Reverse transcription-quantitative PCR (RT-qPCR)
Five hundred nanograms of total RNA was transcribed to cDNA
using the High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Carlsbad, CA, USA). qPCR reactions were performed with
the StepOne Plus System (Life Technologies) using Maxima SYBR green
mix (Thermo Fisher Scientific, Waltham, MA, USA). qPCR primers
published in our previous study were used in this study (Kittaka et al.,
2020). Relative gene expression levels were calculated using a relative-
standard curve method. All gene expression levels were normalized by
the expression level of Hprt.
2.8. Serum ELISA
Mouse TNF-α Duo-Set ELISA kit (R&D Systems, Minneapolis, MN,
USA), mouse TRAP5b assay kit (Immunodiagnostic Systems, Boldon,
UK), and RatLaps CTX-I EIA kit (Immunodiagnostic Systems) were used
to measure serum levels of TNF-α, TRAP5b, and CTX. Serum was se-
parated from blood with Vacutainer collection tube (BD, Franklin
Lakes, NJ, USA) and stored at −80 °C until use.
2.9. Statistics
The two-tailed unpaired Student's t-test was used to compare two
groups. One-way ANOVA with Tukey-Kramer post hoc test was used to
compare three or more groups. GraphPad Prism (ver. 8, GraphPad
Software, La Jolla, CA, USA) was used for all statistical analyses. The p
values< 0.05 were considered significant.
3. Results
3.1. Homozygous gain-of-function mutation in SH3BP2 improves
osteopetrosis in RANKL-deficient mice
We have previously reported that the gain-of-function mutation in
SH3BP2 (Sh3bp2KI/KI), which is responsible for cherubism, increases the
susceptibility of bone marrow-derived M-CSF-dependent macrophages
(BMMs) to TNF-ɑ and stimulates the osteoclast formation independent
of RANKL in vitro (Mukai et al., 2014). Therefore, we hypothesized that
the Sh3bp2KI/KI mutation may improve osteopetrosis in RANKL-defi-
cient (Rankl−/−) mice by inducing osteoclasts.
To test this hypothesis, we created Sh3bp2KI/KI Rankl−/− double
mutant mice. MicroCT analysis found that while the Sh3bp2KI/KI mu-
tation fails to exhibit tooth eruption (Fig. 1A), alveolar bone covering
the tooth is significantly less than Rankl−/− mice (Fig. 1B). The
Sh3bp2KI/KImutation increased the femur length in males, but improved
osteopetrosis by decreasing bone volume/total volume (BV/TV) at
distal femur in male and female Rankl−/− mice (Fig. 1C, D). The
smaller bodyweight of Rankl−/− mice was not restored by the
Sh3bp2KI/KI mutation (Fig. 1E). H&E staining confirmed that the route
for tooth eruption is open more widely and that bone marrow spaces
occupied by hematopoietic cells are more expanded in Sh3bp2KI/KI
Rankl−/− mice than Rankl−/− mice (Fig. 1F, G). These data present
that the Sh3bp2KI/KI mutation improves the osteopetrotic phenotype of
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Rankl−/− mice.
3.2. RANKL-deficient Sh3bp2KI/KI mice develop TRAP+ osteoclasts
To examine whether Sh3bp2KI/KI Rankl−/− mice develop osteoclasts
in vivo, we performed TRAP staining on alveolar and trabecular bone
sections from the mandible and femur of the Sh3bp2KI/KI Rankl−/−
mice. Although the overall TRAP-positive (+) osteoclast number was
much smaller than Sh3bp2+/+ Rankl+/+ mice, a number of TRAP+
multinucleated osteoclasts were developed on the bone surface of
Sh3bp2KI/KI Rankl−/− mice (Fig. 2A, B). The number was increased
toward the growth plate in male Sh3bp2KI/KI Rankl−/− mice (Fig. 2C).
The TRAP+ multinucleated cells were stained positively for an osteo-
clast marker cathepsin K (Fig. 2D). Consistent with the presence of
TRAP+ and cathepsin K+ cells, expression levels of osteoclast marker
genes such as Acp5, Cathepsin K, and Mmp9 were increased in the femur
of Sh3bp2KI/KI Rankl−/− mice compared to Sh3bp2+/+ Rankl−/− mice
(Fig. 2E). Serum TRAP5b levels were elevated in Sh3bp2KI/KI Rankl−/−
mice and serum CTX levels were increased in female Sh3bp2KI/KI
Rankl−/− mice compared to Sh3bp2+/+ Rankl−/− mice (Fig. 2F).
Consistent with our previous results, Sh3bp2KI/KI mutation increased
serum TNF-ɑ levels in Rankl−/− mice (Fig. 2G). In contrast, RANKL
deletion suppressed the elevation of serum TNF-ɑ in Sh3bp2KI/KI cher-
ubism mice (Fig. 2G). Together, the data suggest that Sh3bp2KI/KI
Rankl−/− osteoclasts are functionally active and that TNF-ɑ substitutes
for RANKL to develop TRAP+ osteoclasts in Sh3bp2KI/KI Rankl−/−
mice.
4. Discussion
We have previously shown that bone marrow-derived M-CSF-de-
pendent macrophages harboring a gain-of-function mutation in SH3BP2
are highly susceptible to TNF-ɑ, and they can form TRAP+ osteoclasts
independent of RANKL in vitro (Mukai et al., 2014). In this study, we
showed that the Sh3bp2KI/KI mutation can develop TRAP+ multi-
nucleated osteoclasts in RANKL-deficient mice spontaneously. It also
improved the osteopetrotic phenotype of the mice, presumably coop-
erated with impaired osteoblast function of Sh3bp2KI/KI mice
(Mukherjee et al., 2010; Wang et al., 2010).
To our best knowledge, RANKL-deficient Sh3bp2KI/KI mice are the
third model that develops RANK/RANKL-independent osteoclasts after
the NFkb2−/− and RbpjΔM/ΔM mice injected with TNF-ɑ on the calvaria
(Yao et al., 2009; Zhao et al., 2012). However, they are the first human
disease model that exhibits RANK/RANKL-independent osteoclasto-
genesis. Also, Sh3bp2KI/KI Rankl−/− mice are the second model that
shows the spontaneous osteoclast development in the absence of the
RANK/RANKL signaling following the RbpjΔM/ΔM mice, although Zhao
et al. did not clarify whether TRAP+ cells in the calvaria of PBS-in-
jected Rank−/− RbpjΔM/ΔM mice are osteoclasts or not (in the Fig. 3F of
(Zhao et al., 2012)).
Even though the possibility of RANKL/RANK-independent osteo-
clastogenesis in wild-type mice has been a long-standing debate, many
cell culture studies have suggested the RANK/RANKL-independent os-
teoclastogenesis of wild-type osteoclast precursors (Tanaka, 2017;
Okamoto et al., 2017). Notably, Kim et al. showed that M-CSF/TGF-β-
dependent osteoclast precursors from RANKL- and RANK-deficient mice
are able to form functionally active osteoclasts when stimulated with
TNF-ɑ and IL-1 (IL-1 types are not specified in the report) (Kim et al.,
2005). However, the consequences of TNF-ɑ and IL-1 stimulation in vivo
were not explored in this study.
A recent study by O'Brien et al. showed TRAP+ osteoclast forma-
tion in the K/BxN serum-transfer arthritis model, in which RANK is
deleted by Mx1-Cre (O'Brien et al., 2016). However, it is difficult to
exclude the possibility of incomplete deletion of the Rank gene, because
Cre is inducibly expressed in type I interferon receptor (IFNAR)-ex-
pressing cells after polyinosine-polycytidylic acid (pIpC) injection
(Okamoto et al., 2017; Kuhn et al., 1995). Therefore, the current con-
sensus on RANK/RANKL-independent osteoclastogenesis is that addi-
tional gene manipulation is required for RANK/RANKL-deficient mice
to develop osteoclasts in vivo. Because Sh3bp2KI/KI Rankl−/− mice show
not only a decrease in BV/TV but also an increase in bone resorption
markers in serum compared to Sh3bp2+/+ Rankl−/− mice, homo-
zygous Sh3bp2KI/KI mutation serves as a new genetic manipulation to
enable the formation of functional osteoclasts in the absence of RANKL.
We have previously shown that retroviral overexpression of wild-
type and cherubism mutant form of SH3BP2 in RAW264.7 cells induces
TRAP+ multinucleated cells without RANKL stimulation (Levaot et al.,
2011). We have also shown that TNF-ɑ stimulation in the presence of
SH3BP2 gain-of-function can induce osteoclastogenesis via the SYK-
NFATc1 axis (Mukai et al., 2014). These results suggest that activation
of the downstream signaling of SH3BP2 play a crucial role in RANKL-
independent osteoclast formation. Since the gain-of-function of SH3BP2
increases SYK activation in myeloid cells (Ueki et al., 2007; Mukai
et al., 2014; Yoshitaka et al., 2014), SYK is likely involved in the me-
chanism of RANKL-independent osteoclastogenesis. Pathological con-
ditions caused by the hyperactivation of SYK in myeloid lineage cells
(Puissant et al., 2014; Mocsai et al., 2010; Ozaki et al., 2012) may ex-
hibit bone loss independent of RANKL, at least in part. Individuals with
loss-of-function mutations in RANK or RANKL exhibit osteopetrosis
(Guerrini et al., 2008; Sobacchi et al., 2007). Because tankyrase in-
hibitors can activate the SH3BP2-SYK pathway in osteoclasts by pre-
venting SH3BP2 protein from degradation (Fujita et al., 2018), patients
with certain types of osteopetrosis may benefit from tankyrase inhibitor
treatment by inducing RANK/RANKL-independent osteoclastic bone
resorption.
Elevation of the serum CTX in Sh3bp2KI/KI Rankl−/− mice was sig-
nificant in females, but not in males. The gender-dependent effect may
be explained by the possibility that not all Sh3bp2KI/KI Rankl−/− TRAP
+ cells have active bone resorption capacity in males. In addition, a
supplemental analysis revealed that male Sh3bp2KI/KI Rankl−/− mice
show the increase in serum CTX (p < 0.01) if an outlier is excluded in
each group (Grubbs' method with ɑ = 0.05).
Intriguingly, lack of RANKL decreased the serum TNF-ɑ elevation in
Sh3bp2KI/KI cherubism mice. This result suggests that the RANK-medi-
ated signaling in macrophages plays a critical role in the development
or exacerbation of autoinflammation in cherubism mice. Together,
RANKL inhibitors might be beneficial for suppressing the development
of lesions in cherubism patients. These hypotheses need to be validated
in further studies.
In conclusion, we showed that the cherubism mice carrying the
gain-of-function mutation in SH3BP2 develop osteoclasts in a RANKL-
independent manner. These results will reinforce our current under-
standing that SH3BP2 is an adaptor protein critical for the regulation of
osteoclastogenesis and that additional gene manipulation is necessary
Fig. 1. (A) Representative images showing incisor eruption. Arrowheads indicate erupted incisors in the wild-type mouse at 20 weeks old. (B) Left top: 3D μCT
images of the mandibular molars. Left bottom: 2D coronal μCT images at the yellow line. Right: Percentage of opening width of the tooth measured at the midpoints
of the lower third molar. (C) Left: 3D μCT images of the femur. Right: length of the femur. (D) Left: 2D sagittal μCT images of the femur. Right: Bone volume (BV)/
tissue volume (TV) of trabecular bone. (E) Body weight of the mice. (F) H&E staining of the mandibular third molar. Bar = 100 μm. (G) H&E staining of the femur.
Boxes represent the area shown at higher magnification. Mice were analyzed at 20 weeks old. All images are representative from male mice. Data are mean ± SD.
Each dot in graphs represent a value from a single biological sample. p values in graphs were calculated by one-way ANOVA with Tukey's multiple comparison test.
p < 0.05 was considered to be significantly different.
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Fig. 2. (A) TRAP staining of alveolar
bone surrounding the mandibular third
molar. The boxes represent the area
shown at higher magnification.
Arrowheads indicate TRAP+ cells on
the bone surface. (B) TRAP staining of
trabecular bone of the femur. Boxes
represent the area shown at higher
magnification. Arrowheads indicate
TRAP+ cells on the bone surface. (C).
Left: An image showing the ROI.
Middle: The number of TRAP+ osteo-
clasts/mm2 in each ROI (a, b, c). Right:
The number of TRAP+ osteoclasts/
mm2 from Rankl−/− mice. (D)
Immunohistochemistry of cathepsin K.
Boxes represent the area shown at
higher magnification. (E) qPCR ana-
lysis of osteoclast maker gene expres-
sion in the femur. Average expression
levels in the wild-type mice were set as
1. (F) Serum levels of TRAP5b and
CTX. (G) Serum levels of TNF-α. Mice
were analyzed at 20 weeks old. All
images are representative from male
mice. Data are mean ± SD. Each dot
in graphs represents a value from a
single biological sample. p values in
graphs were calculated by one-way
ANOVA with Tukey's multiple com-
parison test (C) or t-test (E, F, G).
p < 0.05 was considered to be sig-
nificantly different.
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for achieving osteoclastogenesis in the absence of RANK/RANKL.
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